Intelligent Bio Solutions Inc. (INBS)
NASDAQ:INBS
Top Page
Intelligent Bio Solutions
(NASDAQ:INBS)
Select Model
Select Model
Rating:44Neutral
Price Target:
$2.50
▲(142.72% Upside)
Action:ReiteratedDate:03/24/26
The score is held down primarily by very weak profitability and sustained cash burn, reinforced by bearish technicals with the stock trading below major moving averages. Offsetting factors include manageable leverage and positive corporate execution signals (manufacturing scale-up and regulatory progress), but valuation is difficult to support while losses persist and dilution risk remains.
Positive Factors
Manufacturing scale and margin improvement
A strategic manufacturing partnership increased capacity fourfold and targets >40% unit cost savings and ~20 percentage-point gross margin gain. This structural capacity and cost base improvement supports scalable fulfillment, faster commercialization and durable margin expansion as volumes grow.
Negative Factors
Persistent negative cash flow
Substantial and persistent cash burn (~$9.4M operating, ~$9.7M FCF TTM) means the company lacks self-funded growth runway. Continued negative cash flow requires external funding, constrains strategic flexibility, and increases execution risk until operations generate positive net cash.
Read all positive and negative factors
Positive Factors
Negative Factors
Manufacturing scale and margin improvement
A strategic manufacturing partnership increased capacity fourfold and targets >40% unit cost savings and ~20 percentage-point gross margin gain. This structural capacity and cost base improvement supports scalable fulfillment, faster commercialization and durable margin expansion as volumes grow.
Read all positive factors
Intelligent Bio Solutions (INBS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.30M
Dividend YieldN/A
Average Volume (3M)130.15K
Price to Earnings (P/E)―
Beta (1Y)1.60
Revenue Growth3.26%
EPS Growth65.96%
CountryUS
Employees50
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-2.82
Shares Outstanding2,001,173
10 Day Avg. Volume139,467
30 Day Avg. Volume130,152
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)3.03
Price to Sales (P/S)2.97
P/FCF Ratio-0.92
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue1.24
Enterprise Value/Gross Profit4.14
Enterprise Value/Ebitda-0.44
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Intelligent Bio Solutions Business Overview & Revenue Model
Company Description
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor fo...
How the Company Makes Money
INBS generates revenue primarily by selling its drug screening products and associated consumables used with its fingerprint sweat-based testing system. This typically includes sales of single-use test cartridges (or similar disposable tests) and ...
Intelligent Bio Solutions Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
14
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.58M | 3.05M | 3.11M | 1.26M | 0.00 | 1.98M |
| Gross Profit | 1.07M | 1.25M | 1.43M | 326.67K | 0.00 | 1.98M |
| EBITDA | -10.05M | -9.45M | -9.31M | -9.47M | -8.33M | 0.00 |
| Net Income | -11.29M | -10.57M | -10.16M | -10.63M | -8.31M | -7.04M |
Balance Sheet | ||||||
| Total Assets | 17.65M | 8.25M | 13.78M | 10.35M | 12.35M | 21.86M |
| Cash, Cash Equivalents and Short-Term Investments | 740.37K | 1.02M | 6.30M | 1.54M | 8.28M | 12.57M |
| Total Debt | 3.45M | 281.81K | 1.15M | 1.92M | 0.00 | 0.00 |
| Total Liabilities | 6.76M | 5.44M | 5.60M | 6.67M | 5.81M | 6.85M |
| Stockholders Equity | 11.09M | 3.00M | 8.33M | 3.80M | 6.62M | 15.06M |
Cash Flow | ||||||
| Free Cash Flow | -9.74M | -9.91M | -9.79M | -7.88M | -3.74M | -11.30M |
| Operating Cash Flow | -9.38M | -9.68M | -9.57M | -7.38M | -3.36M | -11.30M |
| Investing Cash Flow | -321.38K | -231.84K | -221.43K | -694.14K | -880.22K | 0.00 |
| Financing Cash Flow | 8.16M | 4.60M | 14.56M | 1.44M | 0.00 | 23.40M |
Intelligent Bio Solutions Technical Analysis
Negative
1.03
Price Trends
4.66
Negative
6.56
Negative
10.45
Negative
Market Momentum
-0.59
Negative
29.45
Positive
14.46
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBS, the sentiment is Negative. The current price of 1.03 is below the 20-day moving average (MA) of 3.34, below the 50-day MA of 4.66, and below the 200-day MA of 10.45, indicating a bearish trend. The MACD of -0.59 indicates Negative momentum. The RSI at 29.45 is Positive, neither overbought nor oversold. The STOCH value of 14.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INBS.
Intelligent Bio Solutions Risk Analysis
Intelligent Bio Solutions disclosed 58 risk factors in its most recent earnings report. Intelligent Bio Solutions reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Intelligent Bio Solutions Peers Comparison
UnderperformOutperform
Sector (51)
INBS
Intelligent Bio Solutions
2.65
-9.65
-78.46%
ISPC
iSpecimen
0.15
-1.28
-89.79%
BGLC
BioNexus Gene Lab Corp
2.30
0.13
5.99%
BIAF
bioAffinity Technologies, Inc.
3.92
-14.85
-79.12%
Intelligent Bio Solutions Corporate Events
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Intelligent Bio Solutions Grants Equity Awards, Updates ATM Capacity
Positive
Mar 23, 2026
On March 18, 2026, Intelligent Bio Solutions granted time- and performance-vesting restricted stock to its directors, officers and employees under its 2019 Long Term Incentive Plan, including sizable awards to its CEO and CFO that vest over four y...
Business Operations and StrategyProduct-Related Announcements
Intelligent Bio Solutions Expands Manufacturing Capacity and Deployment
Positive
Feb 25, 2026
On February 25, 2026, Intelligent Bio Solutions announced it had successfully received and deployed the first shipment of its Intelligent Fingerprinting Drug Screening Readers manufactured under a new strategic partnership with Syrma Johari MedTec...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Intelligent Bio Solutions Launches Codeine Screening Clinical Program
Positive
Jan 28, 2026
On January 28, 2026, Intelligent Bio Solutions announced it has begun a new clinical study program to support an FDA 510(k) submission for U.S. market clearance of its non-invasive Intelligent Fingerprinting Drug Screening System for detecting the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.